Related Experiment Video
Updated: Jun 28, 2025
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
1.3K
Review on Emerging Therapeutic Strategies for Managing Cardiovascular Disease
Minal Narkhede1, Avinash Pardeshi1, Rahul Bhagat1
1SMBT College of Pharmacy, Nandi Hills Dhamangaon Taluka Igatpuri, Nashik 422403, India.
Current Cardiology Reviews
|April 17, 2024
Summary
Innovative cardiovascular disease (CVD) treatments are emerging, including new drugs, gene therapy, AI, and digital health tools. These advancements, alongside lifestyle changes, aim to transform CVD management and reduce global health burdens.
Area of Science:
- Cardiology
- Pharmacology
- Biotechnology
- Digital Health
Background:
- Cardiovascular disease (CVD) presents a significant global health challenge with substantial economic implications.
- Traditional therapies for CVD have limitations, necessitating the development of progressive and innovative interventions.
- Understanding the evolving epidemiological landscape of CVD is crucial for effective disease management.
Purpose of the Study:
- To provide a comprehensive overview of the latest advancements in cardiovascular therapeutics.
- To explore emerging pharmacological, biotechnological, and digital health strategies for CVD management.
- To synthesize current knowledge and guide clinicians and researchers in navigating the dynamic field of cardiovascular disease treatment.
Main Methods:
- Review of novel pharmacological interventions, including drug development, targeted therapies, and drug repurposing.
- Exploration of gene therapy, artificial intelligence (AI), and machine learning (ML) in cardiovascular medicine.
- Investigation of non-pharmacological approaches such as digital health technologies, wearable devices, telemedicine, regenerative medicine, and stem cell therapies.
- Analysis of the role of lifestyle modifications, diet, exercise, and behavioral changes in CVD prevention and management.
Main Results:
- Emerging pharmacological strategies offer new avenues for targeted CVD treatment.
- Gene therapy holds potential for addressing genetic predispositions to cardiovascular disorders.
- AI and ML are increasingly integrated for improved risk assessment and treatment optimization.
- Digital health, regenerative medicine, and lifestyle interventions represent transformative tools in CVD care.
- Precision medicine approaches are gaining prominence in tailoring cardiovascular treatments.
Conclusions:
- A synthesis of emerging therapeutic modalities is essential for advancing cardiovascular disease management.
- The integration of novel pharmacological, biotechnological, and digital health strategies promises to transform CVD care.
- Lifestyle modifications remain a cornerstone of cardiovascular health and disease prevention.
- Continued research and collaboration are vital to alleviate the global burden of CVD and promote cardiovascular health.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
498
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
498
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442
01:16Antianginal Drugs: Nitrates and β-Blockers
579
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
579
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K